Analyst Price Target is $19.00
▲ +144.22% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for PolyPid in the last 3 months. The average price target is $19.00, with a high forecast of $24.00 and a low forecast of $14.00. The average price target represents a 144.22% upside from the last price of $7.78.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in PolyPid. This rating changed within the last month from a Strong Buy consensus rating.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.